logo
Search…
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Search...
search
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Home > Latest

Lates News

date
16/07/2026
Citigroup has raised its growth forecast for South Korea's GDP in 2026 from 3.5% to 3.7%.
Latest
2 m ago
Zhi Xiang Golden Ta (688443.SH): Taileqi monoclonal antibody injection adult, severe atopic dermatitis indications for market application accepted for review.
4 m ago
Nobel Prize winner in chemistry Omar Yaghi: China's achievements in the field of artificial intelligence are by no means accidental.
4 m ago
UK Competition and Markets Authority: Letter to private parking lot operators outlining concerns about appeal process and possible unfair additional charges.
5 m ago
Why did Q2 net profit decline compared to the previous quarter? Deming Li's response
5 m ago
Fosun Pharma (02696.HK): The international multicenter Phase 1 clinical study of the biosimilar drug HLX18 (recombinant anti-PD-1 humanized monoclonal antibody injection) developed for various resected solid tumor patients has completed the first global patient dosing in China.
See all latestmore
logo
Contact US
qr
+852 - 60190728
gmteight@futurecultural.com
Customer Support
About Us
Contact Us
Frequently Asked
Privacy Policy
Terms of Use
Commercial Services
Advertising
Business Development
Copyright
Terms of Service
©️2013 - 2026 GMT EIGHT Holdings. All Rights Reserved.